Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Orchard Capital Management LLC

Orchard Capital Management LLC decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,243,426 shares of the biotechnology company’s stock after selling 28,457 shares during the quarter. Heron Therapeutics accounts for about 2.4% of Orchard Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. Orchard Capital Management LLC owned approximately 1.49% of Heron Therapeutics worth $7,852,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Richmond Brothers Inc. grew its position in Heron Therapeutics by 20.2% in the second quarter. Richmond Brothers Inc. now owns 356,558 shares of the biotechnology company’s stock valued at $1,248,000 after acquiring an additional 59,852 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Heron Therapeutics during the second quarter worth approximately $55,000. Wealth Alliance grew its position in shares of Heron Therapeutics by 60.0% during the second quarter. Wealth Alliance now owns 32,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 12,000 shares in the last quarter. Headlands Technologies LLC grew its position in shares of Heron Therapeutics by 731.3% during the second quarter. Headlands Technologies LLC now owns 90,495 shares of the biotechnology company’s stock worth $317,000 after buying an additional 79,609 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Heron Therapeutics during the second quarter worth approximately $127,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $2.02 on Friday. The company has a market cap of $304.32 million, a PE ratio of -3.31 and a beta of 1.80. The company has a fifty day moving average price of $2.36 and a two-hundred day moving average price of $2.78. Heron Therapeutics, Inc. has a 12 month low of $0.50 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same period in the previous year, the company posted ($0.35) earnings per share. Equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on HRTX shares. Rodman & Renshaw started coverage on shares of Heron Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a research report on Wednesday, August 7th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.